Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard H Drew

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
The Journal of Antimicrobial Chemotherapy|March 26, 2010
Echinocandin pharmacodynamics: review and clinical implicationsMelanie W Pound, Mary L Townsend, Richard H Drew
Expert Opinion on Emerging Drugs|August 18, 2011
Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulationsStuart K Pitman, Richard H Drew, John R Perfect
Expert Opinion on Investigational Drugs|July 23, 2004
Novel modes of antifungal drug administrationRebekah R Arthur, Richard H Drew, John R Perfect
Expert Review of Anti-Infective Therapy|March 4, 2009
Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an updateWinter J Smith, Richard H Drew, John R Perfect
International Journal of Clinical Pharmacy|February 1, 2015
Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infectionV Paul DiMondi, Mary L Townsend, Richard H Drew
Expert Review of Anti-Infective Therapy|May 28, 2005
Liposomal amphotericin B: clinical experience and perspectivesWinter J Gibbs, Richard H Drew, John R Perfect
Infection Control and Hospital Epidemiology|December 3, 2025
Comparison of cefazolin administered as a continuous or intermittent infusion for prophylaxis of surgical site infections in adult patients undergoing cardiac or neurologic surgeryRichard H Drew, Nicholas A Turner, Elizabeth Keil, et al.
Infection Control and Hospital Epidemiology|March 8, 2013
Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admissionSteven W Johnson, Deverick J Anderson, D Byron May, et al.
Pharmacotherapy|April 29, 2009
Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaRichard H Drew, Roger White, Conan MacDougall, et al.
Expert Opinion on Pharmacotherapy|February 4, 2003
Antifungal pharmacotherapy for invasive mould infectionsJason C Gallagher, Elizabeth S Dodds Ashley, Richard H Drew, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
The Journal of Antimicrobial Chemotherapy|March 26, 2010
Echinocandin pharmacodynamics: review and clinical implicationsMelanie W Pound, Mary L Townsend, Richard H Drew
Expert Opinion on Emerging Drugs|August 18, 2011
Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulationsStuart K Pitman, Richard H Drew, John R Perfect
Expert Opinion on Investigational Drugs|July 23, 2004
Novel modes of antifungal drug administrationRebekah R Arthur, Richard H Drew, John R Perfect
Expert Review of Anti-Infective Therapy|March 4, 2009
Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an updateWinter J Smith, Richard H Drew, John R Perfect
International Journal of Clinical Pharmacy|February 1, 2015
Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infectionV Paul DiMondi, Mary L Townsend, Richard H Drew
Expert Review of Anti-Infective Therapy|May 28, 2005
Liposomal amphotericin B: clinical experience and perspectivesWinter J Gibbs, Richard H Drew, John R Perfect
Infection Control and Hospital Epidemiology|December 3, 2025
Comparison of cefazolin administered as a continuous or intermittent infusion for prophylaxis of surgical site infections in adult patients undergoing cardiac or neurologic surgeryRichard H Drew, Nicholas A Turner, Elizabeth Keil, et al.
Infection Control and Hospital Epidemiology|March 8, 2013
Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admissionSteven W Johnson, Deverick J Anderson, D Byron May, et al.
Pharmacotherapy|April 29, 2009
Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaRichard H Drew, Roger White, Conan MacDougall, et al.
Expert Opinion on Pharmacotherapy|February 4, 2003
Antifungal pharmacotherapy for invasive mould infectionsJason C Gallagher, Elizabeth S Dodds Ashley, Richard H Drew, et al.
Pageof 5